
1. front immunol. 2019 sep 12;10:2150. doi: 10.3389/fimmu.2019.02150. ecollection
2019.

application modeling approaches explore vaccine adjuvant mode-of-action.

buckley pr(1)(2), alden k(2), coccia m(3), chalon a(3), collignon c(3), temmerman
st(3), didierlaurent am(3), van der r(3), timmis j(2)(4), andersen ca(3),
coles mc(1).

author information: 
(1)kennedy institute rheumatology, university oxford, oxford, united
kingdom.
(2)department electronic engineering, university york, york, united
kingdom.
(3)gsk, rixensart, belgium.
(4)faculty technology, university sunderland, sunderland, united kingdom.

erratum in
    front immunol. 2019 dec 02;10:2905.

novel adjuvant technologies key role development next-generation
vaccines, due capacity modulate duration, strength quality of
the immune response. as01 adjuvant used malaria vaccine rts,s/as01 
and licensed herpes-zoster vaccine (shingrix) vaccine proven
its ability generate protective responses robust humoral t-cell 
responses. many years, animal models provided insights adjuvant
mode-of-action (moa), generally investigating individual genes or
proteins. furthermore, modeling simulation techniques utilized to
integrate variety different data types; ranging serum biomarkers to
large scale "omics" datasets. perspective present framework to
create holistic integration pre-clinical datasets immunological
literature order develop evidence-based hypothesis as01 adjuvant moa,
creating unified view multiple experiments. furthermore, highlight how
holistic systems-knowledge serve basis construction models
and simulations supporting exploration key questions surrounding adjuvant moa.
using systems-biology-graphical-notation, tool graphical representation
of biological processes, captured high-level cellular behaviors and
interactions, cytokine dynamics early immune response, are
substantiated series diagrams detailing cellular dynamics. through
explicitly describing as01 moa built consensus understanding across 
multiple experiments, present framework integrate modeling
approaches exploring adjuvant moa, order guide experimental design,
interpret results inform rational design vaccines.

copyright Â© 2019 buckley, alden, coccia, chalon, collignon, temmerman,
didierlaurent, van der most, timmis, andersen coles.

doi: 10.3389/fimmu.2019.02150 
pmcid: pmc6751289
pmid: 31572370 

conflict interest statement: ca, rm, ad, mc, st report ownership gsk
shares and/or restricted gsk shares.

